Introduction
Among the variety of immunosuppressants available, cyclosporin A (CsA) has been the most extensively used drug to prevent or treat graft-versus-host disease (GVHD) in hematopoietic stem cell transplant (HSCT) recipients, since its introduction in the 1970s. [1] [2] [3] [4] [5] [6] It has been shown that CsA is effective in preventing and controlling acute and chronic GVHD in pediatric patients. 7, 8 However, the use of CsA in the clinical setting is complicated by significant intrapatient and interpatient variability in its pharmacokinetics. 9, 10 Prior reports have shown that there are several factors contributing to this variability, such as age, genetics, the physical condition of patients, type of transplant, post transplant time and concomitant medications. 11 As was previously observed, the major cause for variability is the erratic absorption of CsA. 12 Particularly, HSCT recipients have considerable difference in their gastrointestinal (GI) integrity, as compared to solid organ transplant recipients; these differences are in part caused by GI inflammation that develops after conditioning chemotherapy and radiation treatments and/or intestinal GVHD and viral infection. [13] [14] [15] In addition, a significant factor for the interindividual variability is the patient's intrinsic capacity to metabolize CsA. 12 In general, many drugs administered to children are characterized by a substantially faster elimination than in adults; however, there are limited data on the pharmacokinetics of CsA in pediatric transplant recipients. 16, 17 Some studies have evaluated the pharmacokinetic properties of CsA in children undergoing organ transplantation. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] However, few published data are available for the pediatric HSCT population. 12, 27 Despite the widespread use of CsA, the administration method, dosage schedule and optimal dose of CsA have not been well established, and a variety of treatment protocols have been accepted at numerous transplantation centers. 28 Several studies have suggested that the continuous intravenous (i.v.) infusion of CsA has been effective in preventing acute GVHD in HSCT recipients. 29, 30 Moreover, a continuous infusion is associated with a decrease in the incidence of serious CsA-related toxicities compared with a short i.v. infusion. 29, 31 Based on these data, we administered CsA for a continuous i.v. infusion in the early period after stem cell transplantation; it was continued until the patient could tolerate oral dosing after recovery from treatment-related GI complications. The oral formulation was administered immediately after discontinuation of the continuous infusion with an attempt to maintain CsA levels and provide a practical management option.
The objectives of this study were to study the transition period between continuous i.v. infusion and oral CsA treatment by evaluating the pharmacokinetic properties of CsA in pediatric HSCT recipients.
Patients and methods

Patients
Children who received allogeneic HSCT and CsA for prophylaxis of GVHD at Samsung Medical Center were enrolled in this study. They had normal hepatic function (obilirubin 1.2 mg/dl, SGOT and SGPT o3 Â upper reference limit) and normal renal function (serum creatinine o1.5 mg/dl, infant' criteria o0.6 mg/dl). All patients were treated with a study protocol that had been approved by the Institutional Review Board at Samsung Medical Center. Written informed consent was obtained from parents or guardians before the patients were allowed to enter the study.
Drug administration
Intravenous CsA (Cipol Inj R , 50 mg/ml, CKD, Korea) was started the day before stem cell infusion at a dosage of 5 mg/kg per day as a loading dose; it was given as a continuous infusion through an indwelling catheter. CsA injection was continued, at 3 mg/kg per day, from the day of stem cell infusion and then the dose was titrated to a level of 250-350 ng/ml. Thereafter, the oral formulation was substituted for the i.v. formulation when the patient was able to tolerate oral medications, after they recovered from treatment-related GI complications. The daily oral dose was administered immediately after discontinuation of the continuous infusion, three times the i.v. dose, in two equally divided doses, at 12 h intervals. Soft gelatine capsules (Cipol N R , 25 100 mg/cap, CKD, Korea) or an oral solution (Neoral R , 100 mg/ml, Novartis) were administered, depending on their preference and developmental capability. All patients received anti-fungal prophylaxis with fluconazole, pneumocystis carinii prophylaxis with cotrimoxazole and anti-viral prophylaxis with acyclovir.
Blood sampling
Blood samples were collected during the transition period from i.v. to oral dosing. Whole blood (2 ml) was collected into tubes, with ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. 32, 33 Blood was taken 24 h before the transition, simultaneously from both the peripheral veins and the indwelling catheter lines, at 0 (just before transition), 1, 2, 3, 5, 7, 12 and 24 h after transition via the peripheral lines. As CsA can bind to the plastic tubing of a central line, blood samples were obtained from another lumen that was not involved in the infusion. The first 2 ml of blood was discarded when specimens were drawn from both peripheral veins and indwelling catheter lines. All blood samples were refrigerated until analysis. The results were determined within 48 h after sampling.
Analytic method of cyclosporin A concentration Cyclosporin A concentrations, in whole blood, were measured at the biochemistry laboratory in this center by monoclonal fluorescence polarization immunoassay (FPIA) using commercially available assay kits (TDx, Abbott Laboratories, USA). The operating range for this method is 0-1500 ng/ml but the lower limit of detection is 25 ng/ml. The precision of this method was evaluated using three control concentrations of 150, 400 and 800 ng/ml. The between-day coefficients of variation were 1.3, 1.2 and 1.3%, respectively. The within-run coefficient of variation was estimated to be less than 2.5%. The analytic method used in this study, monoclonal FPIA, showed crossreactivity with some CsA metabolites; however, it was chosen because the results are practically applicable in the clinical setting, and they provide good reproducibility. 34, 35 Pharmacokinetic analysis Pharmacokinetic modeling and parameter estimates were performed using WinNonlin version 3.1 (Pharsight corporation, USA). Utilizing the raw data, such parameters as volume of distribution (Vd, ml/kg), absorption rate constant (Ka, h À1 ), lag time (T lag , h), bioavailability (F,%) and clearance (CL, ml/h/kg) were estimated from the pharmacokinetic model. Then, the elimination rate constant (K e , h
À1
) and elimination half-life (t 1/2 , h) were derived from the primary parameters using the following formulae, respectively: K e ¼ CL/Vd, t 1/2 ¼ 0.693/K e . The peak concentration (C max ) and the time to reach maximum concentration (T max ) were accepted as the observed values.
Statistical analysis
Comparisons of the pharmacokinetic parameters between two groups according to CsA formulations were performed using the two-sided Wilcoxon's rank sum test. For three groups according to patient body weight, the KruskalWallis test was used. Wilcoxon's signed rank test was used to compare the difference of CsA concentrations, in the paired samples, taken simultaneously from both peripheral vein and indwelling catheter sites; the difference in CsA concentrations 24 h before and after the transition time between i.v. and oral treatments were determined. All evaluations were performed using the software package SAS version 8. A P-value of less than 0.05 was considered to imply statistical significance.
Results
Patients
Between April 2002 and November 2003, a total of 33 patients were included in this study. One child was excluded in the final analysis due to the child's failure to take the whole oral dose on the study day. The clinical characteristics are summarized in Table 1 . There were 9 girls and 23 boys with a median age of 7.1 years (range: 0.8-15.6). The body weights ranged from 9 to 74.7 kg. The mean number of days until conversion from i.v. to oral CsA was 25.376.2 days after the stem cell infusion. Twenty-one patients received soft gelatine capsules, and 11 patients were given the oral solution. Of the 32 patients who were enrolled in the study, two patients did not provide concurrent samples from the peripheral veins and indwelling catheter lines.
Pharmacokinetic parameters
The mean concentration for CsA in the whole blood versus time for 32 patients, is illustrated in Figure 1 ; the related pharmacokinetic data is summarized in Table 2 . The interindividual variation in lag time(T lag ) was 60.4% and estimated bioavailability varied between 12.2 and 69.5% (mean 43.1714.4%). After oral administration, the time to peak concentration (T max ) was between 0.4 and 3.6 h (mean 1.970.8 h) after conversion. The volume of distribution ranged from 759 to 4884.9 ml/kg (mean 1871.37 823 ml/kg). The mean for the total clearance was 436.97 124.1 ml/h/kg and the half-life was 3.171.2 h.
Comparison of pharmacokinetic absorption parameters by formulations Patient characteristics for the two groups according to formulations and comparison of their pharmacokinetic absorption parameters are shown in Table 3 . There were no significant differences between CsA soft gelatine capsules and solution in oral absorption for measurements evaluated such as T lag , Bioavailability, C max and T max .
Comparison of pharmacokinetic parameters by body weight
The patient characteristics for the three groups divided by body weight (o20, 20-40 and 440 kg) are presented in Table 4 . None of the comparisons between parameters studied were significant except for drug clearance. Mean clearance (CL) 7s.d. was 480.97103.7, 414.97137.1 and 320751.8 ml/h/kg in patients o20, 20-40 and 440 kg of body weight, respectively. The CsA CL of younger children was significantly greater than for older children (P ¼ 0.044).
Comparison of concentrations in samples obtained simultaneously from different sites
Comparisons of CsA levels were determined from paired specimens taken simultaneously via the peripheral vein and 
Table 2
Summary of CsA pharmacokinetic parameters (n ¼ 32) indwelling catheter sites (Figure 2) . No difference was observed between the concentrations in these two samples (P ¼ 0.94).
Cyclosporin A concentrations with transition from intravenous to oral administration
The average i.v. dose of CsA taken before conversion was 3.470.9 mg/kg per day and the oral dose after conversion was on average 9.7 mg72.5 mg/kg per day. The C max mean value after conversion was 1135.37340.6 ng/ml. The mean CsA concentrations 24 h before and after the i.v.-oral transition time was 332.3795.7 ng/ml and 214.5775.8 ng/ ml, respectively, (Po0.0001). The mean CsA levels 48, 72, 96 h after transition were 287.57150.5 ng/ml, 292.67 116.4 ng/ml and 2727166.1 ng/ml, respectively.
Discussion
Graft-versus-host disease remains a major limiting factor for a successful result after allogeneic HSCT; it affects mortality, morbidity and quality of life. These factors are particularly significant for pediatric patients where the growing body and multiple organ sites are especially All data values are presented as means7s.d. except *(Median (range)). a There were no significant differences between pharmacokinetic parameters of the two groups using the two-sided Wilcoxon's rank sum test. All data values are presented as means7s.d. except *(Median (range)). a There was only significant difference between CL of the three groups using the Kruskal-Wallis test (P ¼ 0.044). vulnerable to the consequences of GVHD. 7 CsA-based immunosuppression has been the most frequently used regimen for prophylaxis and treatment of GVHD in pediatric patients undergoing HSCT, as well as for adults. 7, 8, 17 However, there remains little consensus on the administration scheduling, dosage, and monitoring of CsA. 9, 28 There are some limited data on the pharmacokinetics of CsA in pediatric HSCT recipients as compared to adult transplant recipients; guidelines for CsA therapy, in the pediatric population, are derived from experience with the clinical protocols used for adults. 17 Therefore, a comprehensive understanding of the pharmacokinetics of the CsA in the pediatric HSCT recipients is needed for the development of optimal treatment protocols and valid strategies for therapeutic monitoring.
Following its oral administration, CsA is variably and incompletely absorbed in the GI tract. The mean bioavailability of CsA in adult SCT patients is reported as 34% with a range of 20-50%. 9 The bioavailability of the oral formulation of CsA, in pediatric transplant recipients, is as highly variable as that of the adult population. 17 In our present study, the mean bioavailability of CsA in pediatric SCT recipients was 43.1714.4%. These observed values were a little higher than those reported for pediatric renal transplant patients, 21.8% 22 and pediatric liver transplant patients, 37.6714.6%. 20 The reason for this difference, between kidney transplants and our study patients, may be due to age and small bowel length. Another study has reported that small bowel length is a significant factor for CsA absorption. 23 In the report by Hoppu et al., 22 the study patients had a mean age of 1.76 (1.08-2.53); they were younger children compared to our study patients, and therefore, they may have had a lower bioavailability.
The time to reach C max (T max ) in this study was 1.970.8 h; this is similar to the values reported for other pediatric HSCT groups, 2.471.1 h 15 as well as for pediatric renal transplant recipients, around 1-2 h. 24, 25 As previous studies have reported, the T max for HSCT recipients has shown that absorption is delayed in comparison to that measured in solid organ allograft recipients; 27 it is thought that the differences are due to the presence of GI inflammation caused by mucositis or GVHD. 12, 13, 15 However, we conducted part of our study at a later point in the post transplant period, when GI inflammation was improved; the pharmacokinetics of CsA in HSCT recipients may correspond more closely to those for solid organ transplant recipients during the period of time studied in our investigation.
Comparison of the pharmacokinetic absorption parameters (T lag , Bioavailability, C max , T max ) for the CsA capsules and the oral solution, there were no significant differences between the two formulations in renal transplant recipients 36, 37 or for the heart and lung transplant recipients. 38 Our findings for pediatric HSCT recipients support previous reports concerning the bioequivalence of soft gelatine capsules and oral solution of CsA.
The total clearance of CsA tended to be greater in the pediatric transplant population when compared to the adult transplant groups 16, 17, 19 and patients 0 to 10 years old had a significantly higher CsA CL than those 411 years old. 16 In this study, mean clearance (CL)7s.d. was 480.97103.7, 414.97137.1 and 320751.8 ml/h/kg in patients with o20 kg , 20-40 kg and 440 kg of body weight, respectively. Cyclosporin A CL of younger children was significantly greater than older children (P ¼ 0.044).
In adults with normal renal and hepatic function, the mean elimination half-life has been reported to average between 8.4 and 27 h 27 and in pediatric transplant patients, a shorter half-life has been reported to be between 4.2 and 7.5 h. 17 In our pediatric HSCT recipients, the mean estimated elimination half-life was 3.171.2 h. Owing to the shorter half-life and the higher clearance in the pediatric population, it has been suggested that dosing every 8 h may be more appropriate in children. 15, 17, 21 Several pediatric solid organ transplant centers are using a three times daily dosing schedule instead of twice daily. 39, 40 It has been reported that the three times daily dosing schedule of CsA in children helped to avoid deleterious peak levels with less fluctuation in blood concentration; these results have been obtained without any significant change of the average concentration of CsA. 39 The data in our study suggest that a three times daily dose is useful for pediatric HSCT recipients.
As CsA is a lipophilic molecule, it has been postulated that the drug is adsorbed onto the surface of indwelling catheters, and that it is subsequently leached off when the lines are used for blood sampling. 41 Previous studies have shown that the levels of samples obtained from the lumen used for CsA administration, are significantly higher than those taken from a peripheral vein. 42, 43 In our study, the samples were obtained from an indwelling catheter lumen that was not involved in the CsA infusion; therefore, the mean concentrations for the samples taken 24 h before the transition simultaneously from a peripheral vein and the indwelling catheter, were 332.7791.8 ng/ml and 346.77121 ng/ml, respectively (P ¼ 0.94). The results of our present observations confirm that samples should be drawn from a catherter'lumen that was not used for i.v. CsA infusion, are valid as alternative sites to a peripheral vein for accurate therapeutic drug monitoring.
A variety of CsA administration protocols have been developed and implemented at numerous HSCT centers. These practices range from a 1 h short infusion to a continuous infusion. 28 Previous studies have shown that CsA administration as a continuous i.v. infusion may be more effective, and it is associated with less serious side effects than bolus CsA, for the prevention of GVHD in allogeneic SCT recipients. 13, [29] [30] [31] As a consequence, in some centers CsA is administered as a continuous infusion in the early period after stem cell transplantation. Thereafter, when patients were able to eat normally, usually around 25 days after HSCT, they were converted from i.v. CsA to an oral formulation. The oral formulation was administered immediately after discontinuation of the continuous infusion with the attempt to maintain CsA levels. In other studies, the mean or median C max have been reported as 1200-1500 ng/ml. 20, 37 In our study, the mean peak concentration of CsA (C max ) after oral administration was 1135.37340.6 ng/ml, not excessive C max levels. Therefore, according to this observation, our administration method for the transition period is effective and practical for routine clinical use.
Additional study will further define more specific dosing intervals and conversion doses for oral treatment after continuous intravenous dosing is discontinued. Improved knowledge of doses and time intervals will allow for appropriate adjustments to be made on the basis of pharmacokinetic parameters.
